Repligen Corporation (NASDAQ:RGEN) Shares Sold by Riverbridge Partners LLC

Riverbridge Partners LLC trimmed its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 7.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 422,102 shares of the biotechnology company's stock after selling 32,996 shares during the quarter. Riverbridge Partners LLC owned 0.75% of Repligen worth $53,708,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of RGEN. CIBC Asset Management Inc increased its stake in Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock worth $246,000 after buying an additional 81 shares during the period. Utah Retirement Systems grew its stake in Repligen by 1.1% during the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after purchasing an additional 100 shares in the last quarter. Peapack Gladstone Financial Corp increased its holdings in Repligen by 5.2% during the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after purchasing an additional 103 shares during the period. Signaturefd LLC raised its position in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 124 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of Repligen by 0.8% in the 4th quarter. Arizona State Retirement System now owns 15,410 shares of the biotechnology company's stock valued at $2,218,000 after buying an additional 126 shares during the period. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Canaccord Genuity Group decreased their price target on shares of Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research note on Wednesday, April 16th. HC Wainwright reissued a "buy" rating and issued a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 target price on the stock. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. Finally, Royal Bank Of Canada decreased their target price on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $173.25.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $1.31 on Friday, hitting $118.85. The company had a trading volume of 770,906 shares, compared to its average volume of 738,272. The company has a market cap of $6.68 billion, a PE ratio of -264.11, a PEG ratio of 3.37 and a beta of 1.10. The business has a 50 day moving average of $128.71 and a 200 day moving average of $141.94. Repligen Corporation has a 52-week low of $102.97 and a 52-week high of $182.52. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. Repligen's revenue was up 10.4% compared to the same quarter last year. During the same quarter last year, the business earned $0.28 earnings per share. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.